Organon (OGN) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was $1.574B, down 2% YoY; net income rose to $164M from $160M, while diluted EPS was $0.60 versus $0.61.

• Nine-month revenue declined 2% to $4.592B, while net income increased to $418M from $392M; Jada’s divestiture and favorable FX supported reported results.

Financial highlights

• Q3 gross profit increased 1% to $869M; cost of sales fell 5% to $705M. Nine-month gross profit fell 3% to $2.499B.

• Q3 SG&A rose 1% to $421M and R&D declined 1% to $83M; nine-month SG&A fell 1% to $1.279B and R&D fell 3% to $266M.

• Nine-month operating cash flow was $702M versus $559M; investing cash flow was $266M provided, versus $325M used in 2025.

• Favorable FX added ~$12M, or 1%, to Q3 sales and ~$130M, or 3%, to nine-month sales; excluding FX, sales declined 3% and 5%, respectively.

Outlook and guidance

• The Sun Pharma transaction is expected to close by early 2027, subject to remaining customary closing conditions and regulatory approvals; stockholders approved it in July 2026.

• Miudella U.S. commercial sales are estimated to launch in late 2026; Epyztek in Australia is expected to launch in H1 2027.

• Nexplanon’s EU five-year-use application remains under review, with potential approval in 2027; Vtama international launches are planned for 2026 and beyond, subject to health authority review and approval.

• China VBP is expected to pressure general medicines for several more quarters; supply-chain recovery remains ongoing, with mitigation actions underway.